In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest
 
    Advanced Parenteral Closure Solutions: The Perfect Fit Towards Compliance with EMA GM...
Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights
 
    Exploring Extractable and Leachable Testing Strategies for Parenterals
Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions
 
    Elevating Medication Adherence and Clinical Outcomes with Connected Drug Delivery
Publications, Pharmaceutical, Product Solutions, Drug Delivery Innovations, Brand Differentiation, Market Insights
 
    Aptar Pharma Injectable Expansion – Capacity, Capabilities and Partnership
Publications, Pharmaceutical, Market Insights, Product Solutions
